New drug trial aims to control arthritis in kids
NCT ID NCT06751238
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a drug called secukinumab, given as an IV infusion, in 20 children aged 2 to 17 with juvenile psoriatic arthritis. The main goals are to see how the drug moves through the body and to check its safety over up to 6 years. This is an early-stage trial, so it focuses on dosing and side effects rather than whether the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
secukinumab (a biologic drug given by IV infusion)
What this could lead to
If successful, this could provide a treatment option for children with juvenile psoriatic arthritis that helps control the disease over the long term.
What could go wrong
This is a very early phase 1 study with only 20 participants, so it is primarily checking safety and drug levels, not effectiveness. The drug may cause side effects and may not work for all children.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Ann and Robert H Lurie Childs Hosp
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Childrens Hosp Pittsburgh UPMC
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Cincinnati Childrens Hospital
RECRUITINGCincinnati, Ohio, 45229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Legacy Emanuel Research Hosp Portland
RECRUITINGPortland, Oregon, 97232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Levine Childrens Hospital
RECRUITINGCharlotte, North Carolina, 28203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Texas Arthritis Center
RECRUITINGEl Paso, Texas, 79902, United States
Contact Email: •••••@•••••
Contact
-
Univ Hosp Cleveland Medical Center
RECRUITINGCleveland, Ohio, 44106-5028, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Florida
RECRUITINGGainesville, Florida, 32610 8068, United States
Contact Email: •••••@•••••
Contact